阿仑膦酸钠联合雌激素对绝经后骨质疏松症患者的有效性及骨密度水平的影响  

Effects of alendronate combined with estrogen on efficacy and bone mineral density in patients with postmenopausal osteoporosis

作　　者：邢佳振 石磊 张许萌 赵强[2] Xing Jia-zhen;Shi Lei;Zhang Xu-meng;Zhao Qiang(Department of pharmacy,Daxing District Hospital of Integrated Traditional Chinese and Western Medicine,Beijing,100076,China;Department of pharmacy,Beijing Anzhen Hospital Affiliated to Capital Medical University,100029,China)

机构地区：[1]北京市大兴区中西医结合医院药剂科,北京100076 [2]首都医科大学附属北京安贞医院药事部,北京100029

出　　处：《湖南师范大学学报（医学版）》2021年第2期256-259,共4页Journal of Hunan Normal University(Medical Sciences)

摘　　要：目的:探究阿仑膦酸钠联合雌激素对绝经后骨质疏松症患者的有效性及骨密度水平的影响。方法:回顾性分析2016年4月~2019年1月在我院就诊的150例绝经后骨质疏松症患者的诊疗情况。根据治疗方案不同,分为研究组(87例)和对照组(63例)。对照组给予阿伦磷酸钠治疗,研究组给予阿仑膦酸钠联合雌激素进行治疗。治疗6个月后,分析比较两组患者血清性激素雌二醇(E2)、促卵泡生成素(FSH)、骨钙素(BGP)、抗酒石酸酸性磷酸酶(TRAP-5b)、骨源性碱性磷酸酶(BALP)及骨密度水平。结果:治疗后,两组患者的第二腰椎到第四腰椎(L2-L4)、股骨干、股骨颈、股骨大转子的骨密度值均明显升高,差异有统计学意义;且研究组的上述指标明显高于对照组,差异有统计学意义。治疗后,研究组患者血清E2水平明显高于对照组,FSH水平明显低于对照组,差异有统计学意义。治疗后,研究组患者血清BGP、TRAP-5b、BALP水平均明显低于对照组,差异有统计学意义。两组患者不良反应发生率相比,差异无统计学意义。结论:阿仑膦酸钠联合雌激素治疗绝经后骨质疏松症患者疗效确切,可明显改善患者激素水平,提升骨密度,值得临床推广。Objective To explore the effects ofalendronate combined with estrogen on efficacy and bone mineral density(BMD)in patients with postmenopausal osteoporosis.Methods The clinical?data of 150 cases of patients with postmenopausal osteoporosis who received treatment in our hospital from April 2016 to January 2019 were retrospective analyzed.Patients were divided into study group(87 cases)and control group(63 cases)according to different treatment methods.Patients in the control group were treated with alendronate,while patients in the study group were treated with estrogen on the basis of alendronate.After 6 months of treatment,the serum levels of estradiol(E2),follicle-stimulating hormone(FSH),bone gla protein(BGP),tartrate-resistant acid phosphatase(TRAP-5b),bone alkaline phosphatase(BALP)and BMD of the patients in the two groups were analyzed and compared.Results After treatment,BMD values of the second to fourth lumbar spine(L2-L4),femoral shaft,femoral neck and greater trochanter in the study group and the control group were significantly increased,and the above indexes in the study group were significantly higher than those in the control group.After treatment,the serum level of E2 in the study group was significantly higher than that in the control group,the serum level of FSH was significantly lower than that in the control group,and the differences with statistical significance.After treatment,the serum levels of BGP,TRAP-5b and BALP in the study group were significantly lower than those in the control group,the differences with statistical significance.There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Alendronate combined with estrogen is effective in the treatment of patients with postmenopausal osteoporosis,which can obviously improve the hormone level of patients and the bone density of patients,which is worthy of clinical promotion.

关 键 词：绝经后骨质疏松症 阿仑膦酸钠 雌激素 骨密度 骨代谢标志物 疗效 

分 类 号：R580[医药卫生—内分泌]